New cocktail of drugs aims to stop High-Risk throat cancer in its tracks

NCT ID NCT07385079

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial will test whether adding anlotinib (a drug that cuts off tumor blood supply) to standard immunotherapy and chemotherapy with radiation can improve outcomes for 412 people with high-risk nasopharyngeal cancer. Participants will receive either the new combo or standard treatment. The main goal is to see if the combo delays cancer progression or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anlotinib hydrochloride (a drug that blocks blood vessel growth to tumors), benmelstobart (an immunotherapy), gemcitabine, cisplatin, and radiation therapy
What this could lead to: If successful, this combination could improve how long people with high-risk nasopharyngeal cancer live without their cancer coming back or spreading.
What could go wrong: This is an early-stage Phase 3 trial that hasn't started yet. Adding more drugs may increase side effects, and it's unknown if the benefits will outweigh the risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma nasopharyngeal carcinoma, susceptibility to, 1 nasopharyngeal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CANCER NASOPHARYNGEAL CANCINOMA (NPC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.